{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1196.495",
  "meta": {
    "versionId": "16",
    "lastUpdated": "2021-09-09T01:01:05.000-04:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495",
  "version": "20210909",
  "name": "ICS LABA LAMA Preparations",
  "status": "active",
  "date": "2021-09-09T01:01:05-04:00",
  "publisher": "NHLBI Implementation Science and Health Care Innovation Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version": "05022022",
        "concept": [
          {
            "code": "1945039",
            "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"
          },
          {
            "code": "1945044",
            "display": "14 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"
          },
          {
            "code": "1945047",
            "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler"
          },
          {
            "code": "1945048",
            "display": "30 ACTUAT fluticasone furoate 0.1 MG/ACTUAT / umeclidinium 0.0625 MG/ACTUAT / vilanterol 0.025 MG/ACTUAT Dry Powder Inhaler [Trelegy]"
          }
        ]
      }
    ]
  }
}